London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.
The Madison, Wisconsin-based company is expanding its global operations with distribution deals in Turkey, South Africa, Russia, and Australia.
Lucigen has signed a global agreement with Illumina to be the sole distributor of Epicentre Technologies' genomics kits, enzymes, and ancillary reagents.
The exclusive agreement covers a portfolio of Epicentre products for transposomics, microarray analysis, and transcriptomics research.
The CSPro certification program is a two-step process that includes minimum data generation, data certification, and an on-site audit of a facility and its processes.
The firm presented results of a pre-clinical evaluation of the test and platform yesterday at the Next Generation Dx Summit in Washington, DC.
Lucigen's CEO said the agreement will provide researchers in India with his firm's technologies for use with NGS, cloning, and protein expression systems.
The proceeds will be used to fund development of a molecular diagnostics platform and for clinical trials to gain FDA approval for the platform.
NEW YORK (GenomeWeb) – Using fever to screen for Ebola casts a wide net, while standard RT-PCR requires many hours and expert technicians.
A majority of these assays use standard RT-PCR, but a few have novel methodologies that may help control the current outbreak in Africa, prevent an outbreak in the US, and possibly advance the field of molecular diagnostics.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.